Results and Preclinical Research at Upcoming Conferences
CALGARY, Sept. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced the participation of five of its collaborators and their schedule of presentations at four conferences through November 15, 2008 covering clinical trial results and preclinical research on REOLYSIN(R).
"It's an important time for Oncolytics as we begin to share additional results of our ongoing clinical trial and preclinical research programs for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is the results of these trials that should help us to determine the late-stage clinical path forward for REOLYSIN(R)."
Dr. Kevin Harrington and colleagues are scheduled to present a poster presentation entitled "Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting, being held in San Diego, California from October 31-November 2, 2008.
Prof. Hardev Pandha and colleagues are scheduled to present a poster presentation entitled "A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel to Patients with Advanced Malignancies" at the iSBTc annual meeting.
Dr. Monica Mita et al is scheduled to make two oral presentations, both entitled "A Phase II Study of Intravenous Reolysin (Wild Type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" at the Chemotherapy Foundation Symposium XXVI, being held in New York from November 4-8, 2008 and also at the Connective Tissue Oncology Society (CTOS) meeting, being held in London, U.K. from November 13-15, 2008.
Dr. Anders Kolb and colleagues are scheduled to deliver a poster
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved